Aspirin extended-release tablets

This product belongs to non-steroidal anti-inflammatory drugs. ① Analgesic effect: It is mainly through inhibiting the synthesis of prostaglandins and other substances that can make pain sensitive to mechanical or chemical stimulation (such as bradykinin, histamine), and it belongs to peripheral analgesics. However, the possibility of central analgesia (possibly acting on the hypothalamus) cannot be ruled out; ② Anti-inflammatory effect: The exact mechanism is still unclear. It may be due to the fact that this product acts on inflamed tissues and inhibits the synthesis of prostaglandins or other substances that can cause inflammatory reactions (such as histamine). Inhibition of the release of lysosomal enzymes and leukocyte chemotaxis may also be related to it; ③ Antipyretic effect: It may act on the hypothalamic temperature regulation center to cause peripheral vasodilation, increased skin blood flow, sweating, and increased heat dissipation to play an antipyretic role. This central effect may be related to the inhibition of prostaglandin synthesis in the hypothalamus; ④ Anti-rheumatic effect: The anti-rheumatic mechanism of this product, in addition to antipyretic and analgesic effects, mainly lies in anti-inflammatory effect: ⑤ Inhibitory effect on platelet aggregation: It works by inhibiting platelet cyclooxygenase and reducing the production of prostaglandins.

aspirin

This product is white tablets.

(1) Analgesic, antipyretic (2) Anti-inflammatory, anti-rheumatic (3) Arthritis (4) Anti-thrombotic (5) Pediatric use for the treatment of mucocutaneous lymph node syndrome (Kawasaki disease). (6) Can be used to treat biliary ascariasis.

Antipyretic and analgesic: 2-3 tablets (0.162g per tablet), 3 times a day. Anti-rheumatic: 4-5 tablets (0.162g per tablet), 3-4 times a day, or as directed by a doctor. Children should take a reduced dose.

The doses generally used for antipyretic and analgesic rarely cause adverse reactions. Long-term and large-scale use of the drug (for the treatment of rheumatic fever), especially when the blood concentration of the drug is >200mu;g/m1, is more likely to cause adverse reactions. The higher the blood concentration, the more obvious the adverse reactions. 1 The more common gastrointestinal reactions (incidence 3% to 9%) include nausea, vomiting, upper abdominal discomfort or pain (caused by the direct stimulation of the gastric mucosa by this product), which usually disappear after stopping the drug. Long-term or large-dose use may cause gastrointestinal bleeding or ulcers. 2 Central nervous system: reversible tinnitus and hearing loss occur, which usually occur after a certain course of treatment and the blood concentration reaches 200-300mu;g∕ml. 3 Allergic reactions: occur in 0.2% of patients, manifested as asthma, urticaria, angioedema or shock. Most of them are

The following situations should not be used: 1. Active ulcer disease or gastrointestinal bleeding caused by other reasons; 2. Hemophilia or thrombocytopenia; Those with a history of allergy to aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, angioedema or shock.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. The efficacy is not enhanced when used with other non-steroidal anti-inflammatory drugs, because this product can reduce the bioavailability of other non-steroidal anti-inflammatory drugs. In addition, gastrointestinal side effects (including ulcers and bleeding) are increased; in addition, due to the enhanced inhibitory effect on platelet aggregation, the risk of bleeding in other parts can also be increased. Long-term and large-scale use of this product with acetaminophen may cause kidney diseases including renal papillary necrosis, renal cancer or bladder cancer. 2. When used with any drug that can cause hypoprothrombinemia, thrombocytopenia, reduced platelet aggregation function or gastrointestinal ulcer bleeding, there may be a risk of aggravating coagulation disorders and causing bleeding. 3. When used with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), the risk of bleeding may be increased. 4. Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in urine and reduce the blood drug concentration. However, when the blood drug solubility of this product has reached a stable state, the alkaline drug is discontinued. It can also increase the blood concentration of this product to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis. Not only can it reduce the blood concentration, but it can also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. 5 Uric acid drugs can reduce the excretion of this product and increase its blood concentration. Patients whose blood concentration of this product has reached a stable state may increase the blood concentration of this product and increase toxic reactions after adding uricidification drugs. 6 Glucocorticoids (hormones for short) can increase the excretion of salicylates. In order to maintain the blood concentration of this product when used together, the dose of this product should be increased if necessary. Long-term use of this product and hormones, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. For this reason, it is not recommended to use these two drugs at the same time in clinical practice. 7 The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using them together with this product. 8 When used with methotrexate (MTX), it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. 9 The uric acid excretion effect of probenecid or sulfinpyrazone can be reduced by the simultaneous use of this product; when the blood concentration of salicylate is >50mg/ml, it will be significantly reduced, and even more so when it is >100-150mg/ml. In addition, probenecid can reduce the clearance rate of salicylate from the kidneys, thereby increasing the latter's blood concentration.

Sealed, store in a dry place.

75 mg

24 months

Zhengzhou Xiehe Pharmaceutical Factory

• Founded in:

  1989-12-25

• Address:

  No. 1 Yinhe Road, Huiji District, Zhengzhou

• Tax NO.:

  914101081703110048

• Registered Funds:

  5.33 million yuan

• Website:

  Log in to view

• Email:

  Log in to view